Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

63.51USD
18 Oct 2017
Change (% chg)

$0.29 (+0.46%)
Prev Close
$63.22
Open
$64.01
Day's High
$64.07
Day's Low
$63.41
Volume
2,146,038
Avg. Vol
2,736,306
52-wk High
$66.80
52-wk Low
$58.29

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $172,423.30
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.47
Yield (%): 2.97

Financials

  Industry Sector
P/E (TTM): -- 31.63 16.86
EPS (TTM): -- -- --
ROI: -- 14.92 11.22
ROE: -- 16.17 15.09

BRIEF-U.S. FDA accepts regulatory submission for lynparza

* U.S. FDA accepts regulatory submission for lynparza® (olaparib) in metastatic breast cancer and grants priority review

Oct 18 2017

BRIEF-Merck announces updated overall survival findings from Phase 3 trial of KEYTRUDA

* Merck’s KEYTRUDA® (pembrolizumab) more than doubled median overall survival compared to chemotherapy after two years of follow up in first-line treatment of patients with metastatic non-small cell lung cancer with high levels of PD-L1

Oct 18 2017

Astra and Merck win speedy review for Lynparza in breast cancer

LONDON U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018.

Oct 18 2017

Astra and Merck win speedy review for Lynparza in breast cancer

LONDON, Oct 18 U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018.

Oct 18 2017

BRIEF-Aeglea Biotherapeutics announces clinical collaboration with Merck

* Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer

Oct 16 2017

Merck says will not seek approval of cholesterol treatment

Merck & Co Inc said on Wednesday it will not seek regulatory approval for its experimental cholesterol drug, anacetrapib, as the clinical profile of the treatment does not support regulatory filings.

Oct 11 2017

Merck says will not seek approval of cholesterol treatment

Oct 11 Merck & Co Inc said on Wednesday it will not seek regulatory approval for its experimental cholesterol drug, anacetrapib, as the clinical profile of the treatment does not support regulatory filings.

Oct 11 2017

BRIEF-Merck provides update on Anacetrapib development program

* Merck & Co Inc - ‍Decision follows a thorough review of clinical profile of Anacetrapib, including discussions with external experts​

Oct 11 2017

BRIEF-Kalvista Pharmaceuticals announces collaboration with Merck

* Kalvista Pharmaceuticals announces collaboration with Merck

Oct 10 2017

Roche bladder cancer drug struggles as medics focus on survival

LONDON Roche's immunotherapy drug Tecentriq has lost market share to Merck & Co's rival Keytruda since a clinical trial showed the Swiss company's medicine failed to improve overall survival in bladder cancer.

Oct 05 2017

Competitors

Earnings vs. Estimates